Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Study ID: 2106
NCT Number: NCT03678025
Principal Investigator: Mark Wakefield, MD
Department: Surgery-Urology
Eligibility: Men 18 years old to 100 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
CancerClinicalTrials@health.missouri.edu
